Heather Cheng, MD
Hematology & Oncology · Seattle, WANPI 1467650796
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,175 of the $10,814 with a category attached, or 94.1%. Astrazeneca UK Limited accounts for 69.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $7,535 and has fallen 79.2% since, to $1,564 in 2023.
Across 10 payments — averaging $1081.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$8K
- Janssen Research & Development, LLC$3K
- Sanofi$515
Across 56 payments — averaging $8772.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$295K
- Clovis Oncology, Inc.$171K
- Pharmaand GmbH$25K
What the payments were for
- Consulting fees$10,17594%
- Travel & lodging$3243%
- Food & beverage$3143%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 1 | $7,535 |
| Janssen Research & Development, LLC | 4 | $2,764 |
| Sanofi | 5 | $515 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,814 in reported general payments places this provider in the 75th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 47 | $627,310 |
| XtandiEnzalutamide | 27 | $383,364 |
| OrgovyxRelugolix | 16 | $52,886 |
| Abiraterone Acetate | 61 | $32,977 |
| Bicalutamide | 24 | $463 |
| Prednisone | 59 | $196 |
| Tamsulosin Hcl | 14 | $110 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.